Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis
- 31 August 2005
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 27 (8), 1196-1214
- https://doi.org/10.1016/j.clinthera.2005.07.019
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxibCurrent Medical Research and Opinion, 2005
- Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placeboClinical Therapeutics, 2005
- Parecoxib, Valdecoxib, and Cardiovascular RiskCirculation, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Coxibs and Cardiovascular DiseaseNew England Journal of Medicine, 2004
- Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trialArthritis & Rheumatism, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritisAlimentary Pharmacology & Therapeutics, 2004
- PHARMACOKINETICS AND METABOLISM OF LUMIRACOXIB IN HEALTHY MALE SUBJECTSDrug Metabolism and Disposition, 2004